As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at a recent insider purchase of note.
At CymaBay Therapeutics, a filing with the SEC revealed that on Thursday, Chief Executive Officer Sujal Shah bought 5,000 shares of CBAY, for a cost of $4.30 each, for a total investment of $21,500. So far Shah is in the green, up about 8.6% on their purchase based on today's trading high of $4.67. CymaBay Therapeutics is trading up about 5.9% on the day Tuesday. Before this latest buy, Shah purchased CBAY on 3 other occasions during the past twelve months, for a total cost of $142,554 at an average of $7.13 per share.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.